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Introduction
The link between hormones and breast cancer growth
and development has been recognized for more than 
a century [1]. The concept that hormones are key con-
tributors to carcinogenesis in specific cancers first
emerged in relation to breast cancer in 1896, with the
observation by George Beatson that elimination of
ovarian function, the major source of estrogen, by
means of oophorectomy, could benefit women with in-
operable disease [2]. Furthermore, an association be-
tween the risk of breast cancer and persistently elevated
blood levels of estrogen has been consistently found in
many studies [3]. Estrogen stimulates the proliferation
of breast epithelial cells, and both endogenous and
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SUMMARY
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vivorship in breast cancer patients, with enhancement of disease-free survival and a 50% decrease in recurrences
observed in ER-positive patients 15 years after diagnosis. However, because of the many adverse events in the use
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exogenous estrogens have been implicated in the path-
ogenesis of breast cancer [4–8]. The Women’s Health
Initiative showed that hormone therapy was associated
with a 27% relative increase in invasive breast cancer
(38 vs. 30 cases per 10,000 patient-years) [9], a statis-
tic similar to the 35% increase found in a meta-analysis
of 51 observational studies [10]. A summary of 51 epi-
demiologic studies enrolling 161,116 women with breast
cancer and on hormone therapy showed that breast
cancer risk increased by 2.3% per year of hormone use
(mostly estrogen use) compared with an increased risk
of 2.8% per year of natural delay in the onset of men-
opause [10], suggesting that hormone use increases
the risk of developing breast carcinoma and that this
risk increases with the increasing duration of hormone
use [11]. A review of 19 epidemiologic studies esti-
mated the average breast cancer risk to be 1.18 (95%
confidence interval, CI, 1.01–1.38) with current use of
estrogen alone, and 1.70 (95% CI, 1.36–2.17) with
current use of estrogen–progestin [12]. All these, if 
not the only, studies suggested that estrogen play an
important role in the pathogenesis of breast cancer.
Estrogen and Estrogen Receptors
Classically, estrogen action at target sites around the
body is mediated through related but distinct estrogen
receptors (ERs) designated ERα and ERβ [13], which
then bind as dimers to estrogen-response elements in
the regulatory regions of the estrogen-responsive genes
and associate with basal transcription factors, coacti-
vators, and corepressors to alter gene expression [14],
though recently much evidence has shown the other
pathway, since the presence of specific high-affinity
estrogen binding in non-nuclear subcellular fractions,
including plasma membrane and mitochondria, implies
that the ER could be located at these sites [15]. ERα
and ERβ have 96% amino-acid identity in their DNA-
binding domains, whereas there is only 53% homology
in their ligand-binding domains; the latter accounts for
differences in the responses of the two receptors to
various ligands. For example, tamoxifen (Nolvadex;
AstraZeneca, Wilmington, DE, USA) has been reported
to be both an agonist and an antagonist for ERα, but
only an antagonist for ERβ [3]. The recognition that
tamoxifen and other selective estrogen receptor modu-
lators (SERMs) have tissue-specific agonist–antagonist
activity led to the realization that the classic model was
incomplete and that estrogen action was more com-
plex than had been thought [16,17]. The mechanisms
of the tissue-selective, mixed agonist–antagonist action
of SERMs, though still only partly understood, are
gradually becoming clearer [18]. Most of the unique
pharmacology of SERMs can be explained by three
interactive mechanisms: differential ER expression in 
a given target tissue, differential ER conformation on
ligand binding, and differential expression and binding
to the ER of coregulator proteins [18].
Tamoxifen and Breast Cancer
The accumulating understanding of the mechanism of
action of estrogen led ultimately to the design of anti-
estrogenic agents that work by virtue of their interac-
tion with the ER [13]; these drugs have come to be
known as SERMs. Tamoxifen, a SERM, emerged as the
first antiestrogenic agent that is clinically applicable to
breast cancer [18–37].
Efficacy of Tamoxifen on Breast Cancer
Results of the National Surgical Adjuvant Breast and
Bowel Project (NSABP) trial
Initially approved for the treatment of advanced breast
cancer, tamoxifen was subsequently shown to reduce
contralateral breast cancers by 30–50%, as a second-
ary endpoint in a series of adjuvant studies on early
stage breast cancer [20–23]. Prominent among these
was the NSABP B-14 trial of tamoxifen as adjuvant
hormonal therapy following initial surgical/radiation
treatment of women with localized ER-positive breast
cancer and histologically negative axillary lymph nodes.
Second cancers in the opposite breast were significantly
reduced with tamoxifen versus placebo (p = 0.007).
These observations of tamoxifen’s ability to prevent
second primary cancers in the contralateral breast, to-
gether with its estrogen-directed mechanism of action
and its long half-life, suggested this agent to be a strong
candidate for testing in breast cancer prevention in a
cancer-free but high-risk population of women [24,25].
The following three randomized trials prospectively
evaluated tamoxifen for breast cancer risk reduction
[26–28]. The NSABP P-1 trial, Breast Cancer Preven-
tion Trial (BCPT), was conducted by the NSABP and the
National Cancer Institute from June 1992 to September
1997, during which time 13,388 women of 35 years of
age or older, who were at increased risk of breast can-
cer, were randomized to either 5 years of tamoxifen
(20 mg/day) or placebo [26]. The mean follow-up
time was 47 months and the median time in the study
was 54 months. During the 69 months of follow-up,
175 invasive breast cancers occurred in the placebo
arm, as contrasted with 89 cancers in the tamoxifen
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arm (equivalent to a cumulative incidence of 43.4 per
1,000 women given placebo and 22.0 per 1,000
women given tamoxifen), indicating a 49% reduction
(p < 0.00001) in invasive breast cancers with tamox-
ifen, which led to the US Food and Drug Admin-
istration (FDA)’s approval of tamoxifen for breast
cancer risk reduction in high-risk women [19]. The
benefit of tamoxifen was also seen in the reduction of
noninvasive breast cancers, with 69 in the placebo arm
versus 35 in the tamoxifen arm, representing a 50%
reduction owing to tamoxifen [29].
Results of the International Breast Cancer
Intervention Study I (IBIS-I) trial
The IBIS-I trial showed a 25% reduction in invasive
breast cancer with tamoxifen [30]. A meta-analysis of
these studies [26–28], of which the NSABP P-1 trial
contributed the largest proportion of entered patients,
identified a significant 42% reduction in relative risk of
developing breast cancer associated with tamoxifen
use (relative risk, RR, 0.58; 95% CI, 0.38–0.84) [31].
The absolute risk reduction in these trials was less than
2 per 100 women given tamoxifen for 5 years [33–35].
The absolute risk reduction anticipated in an individ-
ual woman depends on her calculated breast cancer
risk, with women at higher risk having greater potential
benefit. For instance, the average 65-year-old woman
with no family history of breast cancer has an antici-
pated risk reduction of 1 per 100, while a 50-year-old
woman with two affected siblings and two prior bio-
psies but no germline mutation has an anticipated risk
reduction of approximately 2.5 per 100. In an overview
of 37,000 women with breast cancer from 55 trials of
adjuvant therapy, the proportional reduction in recur-
rence was 47% after 5 years of treatment with tamox-
ifen and the proportional reduction in mortality was
26% after 10 years [32]. The absolute improvements in
10-year survival were 10.9% in node-positive and 
5.6% in node-negative breast cancer. Women with 
ER-negative disease had little, if any, benefit [33].
Rationale of 5-Year Tamoxifen Use for
Preventing Breast Cancer
The question then arises as to how long tamoxifen
should be taken. The best results appear to be
achieved after 5 years of treatment; thereafter, benefi-
cial effects decrease and toxicity increases [34–37], al-
though the optimal duration of administration is still
under investigation [18]. Tamoxifen is mainly cytostatic
and slows the proliferation of breast cancer cells by in-
hibiting their progression from the G1 phase of the cell
cycle, but it also induces apoptosis in vitro and thus
may possess cytocidal properties in vivo [29,35]. How-
ever, tamoxifen-stimulated breast cancer has been well 
recognized and provides the rationale for stopping
tamoxifen therapy at 5 years [36].
Potential Adverse Events of Tamoxifen
Tamoxifen was also reported to reduce the risk of 
fractures, though not significantly. However, it was as-
sociated with significantly increased risks of endo-
metrial cancer, stroke, pulmonary emboli, deep vein
thrombosis, and cataracts, primarily in women 50
years of age or older [26,38–44]. Tamoxifen increased
the risk of stroke (RR, 1.75; 95% CI, 0.98–3.20), deep
vein thromboembolism (RR, 1.71; 95% CI, 0.85–3.58),
and pulmonary emboli (RR, 3.19; 95% CI, 1.12– 11.15),
although only the risk of pulmonary emboli reached
statistical significance [26]. The incidence of pulmo-
nary emboli was increased from 0.31 per 1,000 wom-
en per year to 1 per 1,000 women per year [40]. The
incidence of endometrial carcinoma was increased
fourfold, but no deaths due to endometrial carcinoma
occurred in the tamoxifen arm. Endometrial cancer
occurred in 3.05 per 1,000 women per year taking ta-
moxifen [40]. Bernstein et al examined the effect of the
known risk factors for endometrial carcinoma, obesity
and previous estrogen use in women taking tamoxifen;
they found no increase in endometrial cancer with ta-
moxifen use in the absence of these factors [41].
Tamoxifen was also noted to increase the risk of
cataract surgery from 3 per 1,000 to 4.72 per 1,000
per year [26].
Suggestion of the Use of Tamoxifen for
Preventing Breast Cancer
No trial has shown an improvement in survival with
tamoxifen; in fact, there were slightly more deaths in
the tamoxifen group in the IBIS-I trial owing to an ex-
cess of thromboembolic events [30,31]. A recent tech-
nology assessment by the American Society of Clinical
Oncology concluded that tamoxifen’s favorable effect
on the risk of breast cancer must be weighed against
its potential side effects in individual women, conclud-
ing that: (1) for women with a 5-year projected breast
cancer risk of ≥ 1.66%, tamoxifen (at 20 mg/day for 5
years) may be offered to reduce risk; (2) consideration
of tamoxifen is appropriate for the goal of lowering 
the short-term risk of developing breast cancer; (3)
risk/benefit models suggest that the greatest clinical
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benefit with the least side effects are derived from the
use of tamoxifen in younger (premenopausal) women
(who are less likely to have thromboembolic sequelae
and uterine cancer), women without a uterus, and
women at higher breast cancer risk; and (4) data do not
as yet suggest that tamoxifen provides an overall
health benefit or increases survival [29].
Comments on Tamoxifen Use in
Preventing Breast Cancer
With no other competition, tamoxifen became the “gold
standard” and established the principles of tumor tar-
geting and identified the appropriate treatment strat-
egy to aid survivorship in breast cancer patients [1]. A
5-year adjuvant tamoxifen enhances disease-free sur-
vival, and there was a 50% decrease in recurrences ob-
served in ER-positive patients 15 years after diagnosis.
Adjuvant tamoxifen does not provide an increase in
disease-free or overall survival in ER-negative breast
cancer. Five years of adjuvant tamoxifen alone is effec-
tive in premenopausal women with ER. The benefits of
tamoxifen in lives saved from breast cancer far outweigh
concerns about an increased incidence of endometrial
cancer in postmenopausal women. Tamoxifen does not
increase the incidence of second cancers other than
endometrial cancer. No non-cancer-related overall sur-
vival advantage was noted with tamoxifen when given
as adjuvant therapy. Therefore, in the management of
breast cancer, translational research with tamoxifen
targeting the ER with an appropriate duration (5 years)
of adjuvant therapy has demonstrated a contribution
to the falling national death rates from breast cancer.
However, extensive evaluation of tamoxifen treatment
has revealed small but significant side effects, such as
endometrial cancer, blood clots and the development
of acquired resistance. The solution was to develop
drugs, and fortunately, an exploration of the endocrine
pharmacology of tamoxifen and related nonsteroidal
antiestrogens (e.g. raloxifene) resulted in the labora-
tory recognition of selective ER modulation and the
translation of the concept of using raloxifene for the
prevention of osteoporosis and breast cancer. Since
tamoxifen and raloxifene are both SERMs which can
block estrogen-mediated breast cancer growth and
development and also maintain bone mineral density
in postmenopausal women and lower circulating choles-
terol, the following section will discuss the significant
and continuing value of the other SERM, raloxifene,
which has fulfilled its promise as an appropriate medi-
cine that targets specific populations for the preven-
tion of breast cancer [45,46]. The main differences seen
between tamoxifen and raloxifene in relation to their
estrogenic and antiestrogenic properties relates to the
ability of the raloxifene side-chain to interact closely
with amino acid 351, thus further influencing the
function of the ER [1].
Efficacy of Raloxifene on Breast Cancer
Results from the Multiple Outcomes of Raloxifene
Evaluation (MORE) trial
Data on raloxifene’s influence on breast cancer come
almost exclusively from the MORE study, in which
7,705 postmenopausal women with osteoporosis were
randomized to raloxifene at 60 or 120 mg/day (5,129
women) or placebo (2,576 women) for 4 years and
monitored for breast cancer development from the
safety database [19,29,46–51]. The most important
MORE outcome from a cancer perspective is the de-
crease in breast cancer incidence that was observed as
a secondary endpoint in participants taking raloxifene
[47,49,50]. During the 40 months of follow-up, a to-
tal of 54 cases of breast cancer were confirmed, 22
(0.42%) in the raloxifene group and 32 (1.24%) in the
placebo group, with a risk reduction of 65% (RR, 0.35)
[47]. Among the 40 invasive breast cancers, the risk
reduction of 76% (RR, 0.24; 27 with the placebo vs.
13 with raloxifene) was even more striking. The risk re-
duction was similar for both doses of raloxifene and
was limited to ER-positive tumors (RR, 0.10), with no
risk reduction occurring in ER-negative tumors (RR,
0.88) [47]. After 48 months, other results from the
MORE study on breast cancers were reported, includ-
ing 77 verified breast cancers of which 59 were invasive
[49]. Raloxifene use (combining both dosage arms)
continues to be associated with a significant reduction
in relative risk of developing invasive breast cancers
(RR, 0.28; 95% CI, 0.09–0.30; p < 0.001), especially
ER-positive breast cancers [49]. The absolute reduc-
tion in risk of developing breast cancer was 1.4 per
100 women given raloxifene for 5 years’ duration [50].
Continued follow-up of MORE participants using ad-
ditional annual mammograms at 4 years showed an
ongoing breast cancer risk reduction in postmeno-
pausal women treated with raloxifene [50]. Among 61
invasive breast cancers reported as of November 1,
1999, the risk reduction was 72% (RR, 0.28), with 39
(1.51%) using placebo versus 22 (0.43%) using ralox-
ifene. It was more striking to find that the risk reduc-
tion was 84% (RR, 0.16) of the ER-positive breast
cancers, with 31 (1.20%) in the placebo group versus 10
(0.20%) in the raloxifene group. No difference between
the treatment groups was observed in the incidence of
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ER-negative tumors. These observations are consistent
with a model in which raloxifene antagonized estrogen
activity at the ER in the breast [52].
Results from the Continuing Outcomes Relevant to
Evista (CORE) trial
The primary objective of the CORE trial was to investi-
gate the effect of additional 4 years of raloxifene (at
60 mg/day) on the incidence of invasive breast cancer
in postmenopausal women with osteoporosis [53].
During the 4 years of the CORE trial, 61 cases of
breast cancer (30 using placebo vs. 31 using raloxi-
fene) were reported and confirmed by adjudication.
Of the 61 breast cancer cases, 52 (28 using placebo vs.
24 using raloxifene) were invasive breast cancers, with
a 59% reduction in the incidence of invasive breast
cancer in those using raloxifene versus placebo (2.1 vs.
5.2 cases per 1,000 woman-years; hazard ratio, HR,
0.41; 95% CI, 0.24–0.71; p < 0.001). Of the 46 invasive
breast cancer cases, 36 cases (78%) were ER-positive,
with a 66% reduction in the incidence of invasive ER-
positive breast cancers with raloxifene use versus
placebo (1.3 vs. 3.9 cases per 1,000 woman-years; HR,
0.34; 95% CI, 0.18–0.66; p < 0.001). However, there
was no difference in the incidence rates of invasive ER-
negative breast cancer between the raloxifene group and
the placebo group (0.55 vs. 0.61 per 1,000 woman-
years; HR, 1.13; 95% CI, 0.29–4.35; p = 0.86). In addi-
tion, the incidence of noninvasive breast cancer was also
not statistically and significantly different between the
raloxifene and placebo groups (HR, 1.78; 95% CI,
0.37–8.61; p = 0.47). The overall incidence of breast
cancer, regardless of invasiveness, was reduced by 50%
in the raloxifene group compared with the placebo
group (2.7 vs. 5.5 cases per 1,000 woman-years; HR,
0.50; 95% CI, 0.30–0.82; p < 0.001) [53].
Results from the MORE and CORE trials
For the 7,705 MORE participants, the total number of
reported breast cancers confirmed by adjudication
from randomization in the MORE trial to the end of
their participation in either the MORE or CORE trial
was 121 (56 cancers in the raloxifene group and 65 can-
cers in the placebo group) [53]. During the 8 years of
the MORE and CORE trials, 40 invasive breast cancers
were reported in the raloxifene group and 58 in the pla-
cebo group, with a 66% reduction in the incidence of in-
vasive breast cancer with raloxifene use versus placebo
(1.4 vs. 4.2 cases per 1,000 woman-years; HR, 0.34;
95% CI, 0.22–0.50; p < 0.001). Of the 88 invasive
breast cancer cases, 66 (75%) were ER-positive, with a
76% reduction in the incidence of invasive ER-positive
breast cancers with raloxifene use versus placebo (0.8
vs. 3.2 cases per 1,000 woman-years; HR, 0.24; 95%
CI, 0.15–0.40; p < 0.001). There was no difference in
the incidence rates of invasive ER-negative breast can-
cer between the raloxifene group and the placebo
group (0.53 vs. 0.51 per 1,000 woman-years; HR,
1.06; 95% CI, 0.43–2.59; p = 0.90). The incidence of
noninvasive breast cancer was also not statistically
and significantly different between the raloxifene and
placebo groups (16 vs. 7 cases; HR, 1.12; 95% CI,
0.46–2.73; p = 0.80). The overall incidence of breast
cancer, regardless of invasiveness, was reduced by 58%
in the raloxifene group compared with the placebo
group (1.96 vs. 4.9 cases per 1,000 woman-years; HR,
0.42; 95% CI, 0.29–0.60; p = 0.001) [53].
Results from the Raloxifene Use for The Heart
(RUTH) trial
The two primary objectives of the RUTH trial were to
determine the effect of raloxifene as compared with
placebo on the incidence of coronary events (i.e. death
from coronary causes; nonfatal, including silent, myo-
cardial infarction; or hospitalization for an acute coro-
nary syndrome other than myocardial infarction) and
invasive breast cancer [54]. Raloxifene reduced the inci-
dence of the primary outcome of invasive breast cancer
(HR, 0.56; 95% CI, 0.38–0.83; p = 0.003), principally
because of a reduction in ER-positive invasive breast
cancer. The absolute risk reduction per 1,000 women
treated with raloxifene for 1 year was 1.2 cases of in-
vasive breast cancer and 1.2 cases of ER-positive inva-
sive breast cancer. The results of the as-treated analysis
for invasive breast cancer were similar (HR, 0.61; 95%
CI, 0.39–0.95; p = 0.03). There was no significant dif-
ference between treatment groups in the incidence of
ER-negative invasive breast cancer.
Comparison of Tamoxifen and Raloxifene
for Breast Cancer Prevention
As mentioned above, tamoxifen, the first clinically
available SERM, was developed in 1966 and became
the first drug to be approved by FDA for use as a pre-
ventive agent against cancer in 1998, when it was shown
to reduce the incidence of breast cancer in women at
increased risk for the disease by 49% in the BCPT [26].
With no other competition, tamoxifen has remained
the antihormonal therapy of choice for the treatment
of ER-positive breast cancer for the last 30 years.
However, although adjuvant tamoxifen produces pro-
found increases in disease-free and overall survival in
patients with ER-positive breast cancer, concerns about
drug resistance, blood clots and endometrial cancer
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have resulted in a change to the use of aromatase
inhibitors for the treatment of postmenopausal
women [46]. Nevertheless, tamoxifen remains the anti-
hormonal treatment of choice for premenopausal
women with ER-positive breast cancer and for risk re-
duction in premenopausal women who are at high risk
for developing breast cancer [46]. However, tamoxifen
has presented with many potential adverse events,
some of which have contributed to significant morbid-
ity and mortality. Significant improvement in breast
cancer prevention with drug modification is possible if
other competing drugs, which show fewer incidences
of adverse events without compromising the therapeu-
tic effect for breast cancer prevention, are welcome.
Based on the CORE, MORE and RUTH studies
[47,49,52–54], the efficacy of raloxifene in breast can-
cer prevention is clear. Therefore, the question is raised
regarding the possibility of using raloxifene in place of
tamoxifen. Results from the 20,000-women Study of
Tamoxifen and Raloxifene (STAR) were released in
April 2006 [55,56], more than a year ahead of sched-
ule. Raloxifene’s greatest advantage appears to be fewer
serious side effects, including uterine cancer, blood
clots and cataracts, without compromising the breast
cancer chemoprevention strategy. Some important
data from the STAR include: (1) the similar incidence
of invasive breast cancer in both groups (163 cases in
the tamoxifen group vs. 168 cases in the raloxifene
group, 4.30 per 1,000 vs. 4.41 per 1,000; RR, 1.02; 95%
CI, 0.82–1.28); (2) fewer incidences of thromboem-
bolic events (141 cases in the tamoxifen group vs. 100
cases in the raloxifene group, 3.71 per 1,000 vs. 2.61
per 1,000; RR, 0.70; 95% CI, 0.54–0.91); (3) fewer
cataracts (394 cases in the tamoxifen group vs. 313
cases in the raloxifene group, 12.30 per 1,000 vs. 9.72
per 1,000; RR, 0.79; 95% CI, 0.68–0.92) and cataract
surgeries (260 cases in the tamoxifen group vs. 215
cases in the raloxifene group, 8.03 per 1,000 vs. 6.62
per 1,000; RR, 0.82; 95% CI, 0.68–0.99); and (4)
fewer endometrial hyperplasia events with atypia or
without atypia (84 cases in the tamoxifen group vs. 14
cases in the raloxifene group, 4.69 per 1,000 vs. 0.76
per 1,000; RR, 0.16; 95% CI, 0.09–0.29) and hysterec-
tomy (244 cases in the tamoxifen group vs. 111 cases
in the raloxifene group, 13.57 per 1,000 vs. 6.04 per
1,000; RR, 0.44; 95% CI, 0.35–0.56) in the women
taking raloxifene. Although the results did not achieve
statistical significance, they are interesting. There were
fewer cases of noninvasive breast cancer in the tamox-
ifen group than in the raloxifene group (57 vs. 80 cases,
1.51 vs. 2.11 per 1,000; RR, 1.40; 95% CI, 0.98–2.00),
but there were more cases of uterine cancer in the
tamoxifen group than in the raloxifene group (36 vs.
23 cases, 2.00 vs. 1.25 per 1,000; RR, 0.62; 95% CI,
0.35–1.08). In addition, there were no significant dif-
ferences between tamoxifen and raloxifene in patient-
reported outcomes for physical and mental health or
depressive symptoms, and scores on all of these meas-
ures were well within the normal ranges for healthy
women of this age [55], although women in the
tamoxifen group reported having better sexual func-
tion (age-adjusted repeated measure odds ratio,
1.22%; 95% CI, 1.01–1.46), and less mean symptom
severity of musculoskeletal problems (1.15 vs. 1.10;
p = 0.002), dyspareunia (0.78 vs. 0.68; p < 0.001) and
weight gain (0.82 vs. 0.76; p < 0.001). However,
women in the raloxifene group reported benefits in
relation to gynecologic problems, vasomotor symp-
toms, leg cramps and bladder control, because they
had greater mean symptom severity for gynecologic
problems (0.29 vs. 0.19; p < 0.001), vasomotor symp-
toms (0.96 vs. 0.85; p < 0.001), leg cramps (1.10 vs.
0.91; p < 0.001) and bladder control symptoms (0.88
vs. 0.73; p < 0.001) [56].
Conclusion
According to the concept of tamoxifen for chemopre-
vention of invasive breast cancer and the long-term
tolerance of the many adverse events with tamoxifen
use, raloxifene is a significantly better alternative since
the STAR trial clearly demonstrated the superiority of
raloxifene over tamoxifen not only for the equal effi-
cacy in the prevention of invasive breast cancer but also
for fewer serious adverse events, including thromboem-
bolism. Since raloxifene is approved by the FDA for the
prevention of breast cancer, primary care physicians
may be more willing, given their experience with ralox-
ifene, to prescribe it for breast cancer chemoprevention
than to prescribe tamoxifen.
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